scout
|Articles|March 9, 2011

Oncology & Biotech News

  • December 2010
  • Volume 4
  • Issue 12

FDA Approves Zactima

Author(s)OBTN

An FDA advisory panel voted 10 to 0 in favor of approving Zactima (vandetanib) for patients with medullary thyroid cancer who have symptomatic, progressive disease.

An FDA advisory panel voted 10 to 0 in favor of approving Zactima (vandetanib) for patients with medullary thyroid cancer who have symptomatic, progressive disease. The panel expressed concerns about “substantial” drug-related toxicity associated with the 300-mg daily dose. Members said that patients taking Zactima appeared to be at greater risk for stroke and other cerebrovascular events and a prolonged QT interval.

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME